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Abstract
Estrone and estradiol are both estrogens with estrone being the less potent form and estradiol being the most potent
estrogen. The binding of the latter to cellular regulatory elements stimulates the proliferation of breast cancer cells. A high
ratio of estradiol/estrone is related to increased cell proliferation, and is of great importance to understanding of breast
cancer mechanisms. 17beta-hydroxysteroid dehydrogenase type 1 and type 2 play important roles in the activation of
estrone and inactivation of estradiol. Breast cancer cells T47D, MCF-7, BT 20, and JEG 3 as control cells, were chosen to
evaluate the contribution of these two enzymes to the ratio. Twenty four hours after addition of different concentrations of
estrone and estradiol, the ratio stabilized to around 9/1 in breast cancer cell lines with high expression of type 1 (T47D, BT
20, and JEG 3), whereas it approached 1/5 in cells with low expression of type 1 (MCF-7). The estradiol/estrone
concentration ratio was modified to 9/1 in MCF-7 and HEK-293 cells over-expressing type 1. In T47D and BT 20, this ratio was
decreased from 9/1 to nearly 1/5 (19/81 and 17/83 respectively) after type 1 knockdown by specific siRNAs. Type 2 is mainly
involved in the conversion of estradiol into estrone. This ratio was decreased from 9/1 to 7/3 after over-expression of type 2
in MCF-7 cells already over-expressing type 1. The ratio was further decreased by the addition of the oxidative cofactor,
NAD, to the cell culture to facilitate the estradiol to estrone conversion catalyzed by type 2. These results demonstrate that
the estradiol/estrone ratio is controlled by both type 1 and type 2 with an additional contribution by NAD, although type 1
is the first determining factor in the cellular environment compared with type 2 and cofactors. Moreover, kinetic studies
were carried out in intact cells as a new approach, using HEK-293 cells over-expressing type 1 and T47D breast cancer cells.
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Introduction
Breast cancer is one of the major causes of death in western
women, with a 10% risk of survival [1]. In 2009, new breast cancer
cases (192,370) were considerably more common than new lung
cancer cases in US women (103,350) [2,3]. Most breast cancer
cases are estrogen dependent. Both the potent estrogen, estradiol
(E2), and the less potent estrone (E1) are present in cancer cells [4].
E2 binds to estrogen receptors (ERa and ERb) or to the G protein-
coupled membrane receptor (GPR30), then recruits promoters of
several genes related to proliferation, thus stimulating cell growth
[1,5,6]. The high ratio of [E2]/[E1] (hereafter simplified as the
ratio) in the cellular environment contributes significantly to BC
cell proliferation [7]. In addition, the intratumoral [E2]/[E1] ratio
was found to be significantly higher in postmenopausal women
with a higher risk of breast cancer than in premenopausal women
[8,9], so decreasing this ratio (decreasing the production of E2)
could be critically important for the therapy of breast cancer.
17beta-hydroxysteroid dehydrogenases (17b-HSDs) are impor-
tant for the last step of estrogen and androgen activation and the
first step of their degradation. E1 can be converted to E2 by
reductive 17b-HSDs, and E2 can be converted to E1 by oxidative
17b-HSDs [10–13]. The highly active 17b-HSD1 plays an
important role in E2 synthesis using NADPH as cofactor, with a
Km value of 0.0360.01 mM [14]. 17b-HSD2 plays an important
role in E1 production using NAD as cofactor, with a Km value of
0.3560.09 mM [15]. In some estrogen-dependent breast cancer
cells, 17b-HSD1 is more abundantly expressed than 17b-HSD2
[16–18]. Using the purified protein it has been shown that 17b-
HSD2 catalyzes E2 inactivation at a somewhat lower specific
activity than that of E1 activation by 17b-HSD1, but it
demonstrates much higher oxidative activity when compared to
the other enzymes in the family known to date [19].
It has been reported that 17b-HSD1, 17b-HSD2 and the
cofactor play important roles in the [E2]/[E1] ratio in HEK-293
cells over expressing the respective genes. The ratio of 92/8 in
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was changed to 5/95 with overexpression of 17b-HSD2 [20].
Cofactors are also important for the conversion of estrogens.
Recently, it has been demonstrated that this ratio was modified to
1/9 after mutagenesis of cofactor binding site R38 in HEK-293-
17b-HSD1 [16]. The conversion rate of E2 to E1 was not changed
significantly, after variation of the cofactor binding site in HEK-
293-17b-HSD2 [16]. The evaluation of their importance to the
[E2]/[E1] ratio in breast cancer cells (BC cells) requires further
study in order to understand the mechanism of these estrogen
dependence BC cells.
In this study, the contributions of 17b-HSD1, 17b-HSD2 and
cofactor to the [E2]/[E1] ratio have been investigated directly
from experiments in BC cells, as metabolite concentration ratios as
proxies for metabolomics are becoming more common [21]. Our
approach involved knocking down of 17b-HSD1, and simulta-
neous over-expression of 17b-HSD1 and 17b-HSD2 in BC cells to
evaluate their contribution to this ratio. The results demonstrate
that the expression of 17b-HSD1, is critically important for
determining the [E2]/[E1] ratio in BC cells.
Results
1. Contribution of 17b-HSD1 to [E2]/[E1] ratio in breast
cancer cells
The [E2]/[E1] ratio was analyzed in several cell lines after
being cultured in presence of different concentrations of E1 and
E2 for 24 hours. ER positive cell lines T47D and MCF-7, two
other cell lines expressing 17b-HSD1 including an ER negative
cell line BT 20, and a choriocarcinoma cell line JEG 3 as a control
were used. Four different concentrations of E1 and E2 (0.01 mM,
0.05 mM, 0.1 mM and 0.3 mM) were added to the medium. The
ratio was around 9/1 after incubation with E1 or E2 for 24 hours
in all these chosen cell lines with high expression of 17b-HSD1
(including T47D, BT 20 and JEG 3) [17,22], whereas it was less
than 1/5 in MCF-7 cells which have a low expression of 17b-
HSD1 (figure 1 and figure 2). The ratio stabilized after incubating
different concentrations of E1 and E2 for 24, 48 and 72 hours,
indicating that the system was in dynamic equilibrium.
Our results demonstrate that the ratio is maintained (around 9/
1) in cell lines with high expression levels of 17b-HSD1, regardless
of the concentration or steroids added to the culture medium.
Proliferation of T47D and MCF-7 cells was evaluated after
treatment with four different concentrations of E1. There was no
significant increase of cell numbers after 24 hours, demonstrating
that there is no correlation between this ratio and cell proliferation
in the period when the ratio is evaluated.
The ratio was decreased from 9/1 to 19/81 in T47D cells after
treatment with 17b-HSD1specificsiRNAs, and was decreased from
9/1 to 17/83 in BT 20 cells after knocking down of 17b-HSD1
(figure 3). The ratio was increased to 9/1 after over-expression of
17b-HSD1 in HEK-293 cells and was increased from 1/5 to 9/1
after over-expression of 17b-HSD1 in MCF-7 cells (MCF-7-17b-
HSD1). The expression level of 17b-HSD1 is thus a determining
factor for the high ratio of [E2]/[E1] in BC cells.
2. The contribution of 17b-HSD2 to [E2]/[E1] ratio
In addition to 17b-HSD1, 17b-HSD2 also plays an important
role in estrogen conversion, particularly for conversion of estradiol
to estrone. MCF-7 cells were chosen to test the contribution of
17b-HSD1 and 17b-HSD2 to this ratio. MCF-7 cells over-
expressing 17b-HSD1, those over-expressing 17b-HSD 2, and
those over-expressing both 17b-HSD1 and 17b-HSD2 (MCF-7-
17b-HSD-1&2) were constructed to evaluate this ratio (figure 4).
The ratio was 1/9 in MCF-7-17b-HSD2. It was 9/1 in MCF-7-
17b-HSD1, and decreased to 7/3 in MCF-7-17b-HSD1 after over
expression of 17b-HSD2.
Cofactors also influence this ratio. E1 can be activated by 17b-
HSD1 using the reductive cofactor NADPH, and E2 can be
inactivated by 17b-HSD2 using the oxidative cofactor NAD. After
addition of 0.5 mM NAD to the culture medium of MCF-7-17b-
HSD-1&2, the conversion of E1 to E2 was decreased from 75.1%
to 49.8%, and the conversion of E2 to E1 was increased from
27.2% to 57.6% (figure 5), both of them due to the increased type
2 oxidation. The ratio was unchanged by the addition of 0.5 mM
NAD to the medium of T47D and MCF-7-17b-HSD1 cells. Thus,
a decrease in [E2]/[E1] ratio is not caused by facilitating the
oxidative reaction catalyzed by 17b-HSD1. The ratio is not
affected by the addition of NAD in these two cell lines due to the
fact that only tri-phosphate cofactors are specific for type 1
enzyme, as demonstrated by the enzyme structure and kinetic
studies [14,23]. Cell proliferation was investigated by the addition
of 0.5 mM NAD to MCF-7-17b-HSD-1&2 cells. The decrease in
[E2]/[E1] ratio was not a result of cell proliferation decrease after
treatment of these cells with NAD. This demonstrates that 17b-
HSD2 oxidation can be facilitated by increasing the NAD
concentration and shows that the ratio is determined by the
expression levels of 17b-HSD1, 17b-HSD2 and cofactors. Both of
them are major determinants of this ratio in breast cancer cells
while 17b-HSD1 comes for the first.
3. The enzyme kinetics of 17b-HSD1 activation of estrone
in intact cells
17b-HSD1 is important during the activation of estrogen. The
enzyme kinetics have been studied with purified enzyme [14,23],
but not in a cellular context. HEK-293-17b-HSD1 and T47D cells
(in which 17b-HSD1 dominates the conversion of E1 to E2) were
chosen to study the steady-state kinetics of E1 activation in a
cellular system. Different concentrations of E1, varying from
0.01 mM to 0.3 mM, were added to the medium. The apparent
Km values were 0.2560.04 mM and 0.1260.02 mM for E1 to E2
conversion in HEK-293-17b-HSD1 and T47D respectively
(figure 6).
Discussion
A high level of E2 is positively correlated to breast cancer risk
[24,25], as this potent estrogen plays an important role in the
proliferation of cancer cells [26]. It has been confirmed by
microarray analysis that some genes related to cell growth and
differentiation are regulated by E2, including PR (progesterone
receptor), EREs (estrogen response elements), pS2 and cathepsin
D [27,28]. So a high [E2]/[E1] ratio in the cellular environment is
closely related to the proliferation of BC cells and decreasing this
ratio thus gives some insight into the therapy of breast cancer [4].
17b-HSDs are considered to be the main enzymes involved in
the conversion of estrogens or androgens [5,29,30]. It has been
proposed that 17b-HSD1 and 17b-HSD2 have important roles in
determining the [E2]/[E1] ratio in HEK-293 where they are
overexpressed [20]. Ratios of 9/1 in HEK-293-17b-HSD1, and 1/
9 in HEK-293-17b-HSD2 have been reported [20]. In this study
the [E2]/[E1] ratio was tested in BC cells and was found to be 9/1
in both ER positive and negative cells with a higher expression of
17b-HSD1. The ratio was decreased after knocking down the
expression of 17b-HSD1 both in ER-positive cells and ER-
negative cells, and it was increased from 1/5 in MCF-7 cells to 9/1
in MCF-7-17b-HSD1 cells. This demonstrates that the high ratio
is positively correlated with 17b-HSD1 expression, while not
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significant changes have been found for E1 to E2 conversion
after knocking down other 17b-HSD reductive enzymes (data was
not published), suggesting that 17b-HSD1 is a dominant factor in
the maintenance of this ratio compared to other 17b-HSDs in
breast cancer cells.
Figure 1. The conversion of E1 to E2 in T47D, MCF-7, BT 20, JEG 3, HEK-293-17b-HSD1 and MCF-7-17b-HSD1 cells. 50,000 cells were
seeded onto 24-well plates, and different concentrations of E1 (0.01 mM, 0.05 mM, 0.1 mM and 0.3 mM) were added to dextran-coated charcoal treated
medium. E2 production was evaluated every 0 h, 2 h, 4 h, 6 h, 8 h and 24 h. Choosing 0.01 mM, 0.05 mM, 0.1 mM and 0.3 mM E1 as the substrate are
represented by green, red, blue and black lines respectively. Experiments were performed in duplicate, and all the data are fit to sigmoidal or
exponential distribution (S.D.#1%).
doi:10.1371/journal.pone.0029835.g001
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estrogen oxidation. The [E2]/[E1] ratio was decreased from 9/1
to 7/3 after over expression of 17b-HSD2 in MCF-7-17b-HSD1.
This is consistent with the previous report that this ratio was
slightly decreased after over expression of 17b-HSD2 in T47D
cells [17]. Hence both 17b-HSD1 and 17b-HSD2 contribute to
Figure 2. The conversion of E2 to E1 in T47D, MCF-7, BT 20 and JEG 3 cells. 50,000 cells were plated onto 24-well plates, and different
concentrations of E2 (0.01 mM, 0.05 mM, 0.1 mM and 0.3 mM) were added to dextran-coated charcoal treated medium. E1 production was evaluated at
0 h, 2 h, 4 h, 6 h, 8 h and 24 h. Choosing 0.01 mM, 0.05 mM, 0.1 mM and 0.3 mM E2 as the substrate are represented by green, red, blue and black lines
respectively. Experiments were performed in duplicate, and all the data are fit to sigmoidal or exponential distribution (S.D.#1%).
doi:10.1371/journal.pone.0029835.g002
Figure 3. The conversion from E1 to E2 in T47D, BT 20 and JEG 3 cells after knocking down 17b-HSD1. A. 17b-HSD1 expression levels
after being treated with specific siRNAs and control siRNAs (mixed SNC1 siRNA and scramble siRNA) in T47D cells. 200,000 cells were seeded onto 6-
well plates, the cells were transfected with 100 nM mixed specific siRNAs for 17b-HSD1 or control siRNAs for 48 hours, then western blot was carried
out. GADPH was chosen as the internal control protein. B. The conversion from E1 to E2 in T47D, BT 20 and JEG 3 cells after being treated with 17b-
HSD1 specific siRNAs.
doi:10.1371/journal.pone.0029835.g003
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cellular environment, consistent with its high activity.
The choice of cofactor is another important factor in the
conversion of E1 to E2. The conversion of E2 to E1 can also be
catalyzed by 17b-HSD1 with lower activity in vitro. During this
oxidative conversion, the Kcat/Km value using NADP is 9.75
times greater than that obtained using NAD, so NADP is
preferred during the oxidative conversion catalyzed by 17b-
HSD1 [14]. [E2]/[E1] ratio was unchanged by the addition of
0.5 mM NAD to T47D and MCF-7-17b-HSD1 cells (with higher
expression of 17b-HSD1 and lower expression of 17b-HSD2),
whereas it was decreased by the addition of 0.5 mM NADP. The
Kcat/Km value for 17b-HSD2 using NAD is 400 times greater
than that using NADP, so NAD is the preferred cofactor for its
major role in E2 oxidation [15]. In addition, the specificity of
17b-HSD2 to NAD is around 3 times higher than that of 17b-
HSD1 [14–16]. [E2]/[E1] was further decreased from 7/3 to 1/1
by the addition of 0.5 mM NAD to MCF-7-17b-HSD-1&2 cells,
but it was not significantly changed by the addition of 0.5 mM
NAD to MCF-7-17b-HSD-1 cells. The decrease in this ratio in
MCF-7-17b-HSD-1&2 cells by addition of NAD is due to
facilitation of the oxidation catalyzed by 17b-HSD2. Furthermore it
has been confirmed that the decrease in [E2]/[E1] ratio after
addition of 0.5 mM NAD as the cofactor is not due to cell death. In
the cellular environment, 17b-HSD1 reductionis predominant over
its oxidation to yield the high [E2]/[E1] ratio, for which 17b-HSD1
is of the first importance as compared to 17b-HSD2 and cofactor in
BC cells.
17b-HSD1 kinetics have been studied using purified enzyme
[14,23]. The apparent affinity is different for different cofactors
such as NADP, NADPH, NAD and NADH. NADPH has the
highest specificity for the conversion of estrogens. The Km value
of estrone activation by purified 17b-HSD1 using NADPH is
0.0360.01 mM. Until now, the Km value of 17b-HSD1 in the
cellular environment has not been extensively studied. HEK-293-
17b-HSD1 and T47D were chosen to measure the Km value in
intact cells. Although other reductive 17b-HSDs enzymes (17b-
HSD5, 17b-HSD7 and 17b-HSD12) can convert E1 to E2 in
T47D, it has been shown that 17b-HSD1 is the dominant
enzyme for this catalysis in the cell line [18,31]. This
demonstrates the high specificity of 17b-HSD1 for the estrone
substrate. The apparent Km value for 17b-HSD1 is 4–8 times
larger in the cellular environment compared to the purified
enzyme.
Figure 4. Western blots of 17b-HSD1 (A) and 17b-HSD2 (B) with over expressing in MCF-7. 100,000 cells were seeded onto 6-well plates,
the cells were transfected with plasmid with over expressing of 17b-HSD1 and 17b-HSD2, then western blot was carried out after 48 hours. GADPH
was chosen as the internal control protein.
doi:10.1371/journal.pone.0029835.g004
Figure 5. The conversion from substrate to product in MCF-7, MCF-7-17b-HSD1, MCF-7-17b-HSD1&2, MCF-7-17b-HSD1&2 with
adding 0.5 mM NAD. Except MCF-7-17b-HSD2 using E2 as the substrate, E1 was chosen as the substrate in MCF-7, MCF-7-17b-HSD1 and MCF-7-
17b-HSD1&2.
doi:10.1371/journal.pone.0029835.g005
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A high [E2]/[E1] ratio is positively correlated to the
proliferation of BC cells [7], and its reduction is suggested to be
an effective means of facilitating breast cancer therapy. This ratio
was around 9/1 in BC cells with a high expression level of 17b-
HSD1. The ratio was significantly increased in MCF-7-17b-HSD1
compared to MCF-7 cells, but was decreased after knocking down
17b-HSD1 in T47D and BT 20 cells. The ratio decreased with the
additional expression of 17b-HSD2 in MCF-7-17b-HSD1, and
further decreased with adding oxidative cofactor NAD in the
culture medium. 17b-HSD1 remains the first determinant of the
high ratio in BC cells when compared to17b-HSD2 and cofactors.
Furthermore, the kinetic studies were carried out in HEK-293-
17b-HSD1 and T47D cells, demonstrating the high apparent
specificity of this enzyme to the estrone substrate.
Materials and Methods
Chemicals
The E1 and E2 radiochemicals were obtained from American
Radiolabeled Lab (St. Louis, MO), and unlabeled steroids were
purchased from Sigma (Oakville, Ontario, Canada). Allsteroids were
dissolved in ethanol. NAD cofactor was purchased from Sigma.
Cell culture
ER positive cell lines T47D and MCF-7, ER negative cell line
BT 20, HEK-293 cells, and the choriocarcinoma cell line JEG 3
were obtained from American Type Culture Collection (ATCC,
Manassas, VA). MCF-7 cells were maintained in DME low-
glucose medium. T47D cells were propagated in DME high-
glucose medium containing 7.5 mg/L bovine insulin (Sigma,
Oakville, Ontario, Canada). Phenol red-free medium was used.
BT 20, JEG 3 and HEK-293 cells were cultured in MEM
medium. All the media were supplemented with 10% FBS, and
cultured in an incubator at 37 C under 5% CO2 humidified
atmosphere.
siRNA synthesis, plasmid construction and transfection
17b-HSD1 siRNA was designed according to the previous study
[7]. siRNA transfections were carried out by lipofectamine 2000
(Invitrogen, Burlington, Ontario, Canada), following the manu-
facturer’s instructions. 40,000–50,000 cells were seeded onto the
24-well plates one day before transfection, and 100–200 nM
mixed siRNA duplexes were transfected. Silencer negative control
siRNA (Ambion, Austin, TX) and scramble siRNA (GenePharma,
Shanghai, China) were used as control siRNAs. Three pairs of
siRNAs were synthesized for 17b-HSD1, including siRNA 1 (59-
GCUGGACGUGAAUGUAGUATT-39,5 9- UACUACAUU-
CACGUCCAGCTT-39), siRNA 2 (59- GCCUUUCAAUGAC-
GUUUAUTT-39,5 9- AUAAACGUCAUUGAAAGGCTT-39)
and siRNA 3 (59- CCACAGCAAGCAAGUCUUUTT-39,5 9-
AAAGACUUGCUUGCUGUGGTT-39) [7].
Human 17b-HSD1 and 17b-HSD2 cDNAs were amplified
using specific primers, and the fragments were inserted into the
pcDNA3.1 (+) vector. Recombinant plasmids 17b-HSD1 and 17b-
HSD2 were transfected into cells with lipofectamine 2000.
200,000 MCF-7 cells over-expressing 17b-HSD1 and 17b-HSD2
were seeded onto 6 well-plates. All the enzyme activity analyses
were carried out after being treated with siRNAs and recombinant
plasmid for 48 hours.
Western blot
Total protein was extracted from cells lysed with RIPA buffer
supplemented with 1 mM Phenylmethanesulfonyl fluoride and a
protein inhibitor cocktail (Santa Cruz Biotechnology, Santa Cruz,
CA). Equal amounts of total protein were loaded onto a 12% SDS
polyacrylamide gel and transferred onto a nitrocellulose membrane
(PerkinElmer, Waltham, MA). The membrane was blocked with
5% nonfat milk in PBS-Tween buffer overnight. The membrane
was further incubated with PBS-Tween buffer containing a 1:
100,000 dilution of the primary anti-17b-HSD1 rabbit polyclonal
antibody (Abcam, Cambridge, MA) or 1: 1,500 dilution of primary
anti-17b-HSD2 mouse polyclonal antibody (Abcam, Cambridge,
MA). The respective horseradish peroxidase-conjugated antibody
(Santa Cruz Biotechnology) was chosen as the secondary antibody
and was diluted by a factor of 6,000. Protein signals were visualized
with chemiluminescence reagent (PerkinElmer).
Activity assay in several cell lines
50,000 cells were plated onto 24-well plates for testing enzyme
activity. Different concentrations of [14C] E1 and [14C] E2
(0.01 mM, 0.05 mM, 0.1 mMa n d0 . 3mM) were added to the medium
treated with dextran-coated charcoal. The cell supernatants were
collected after incubation at 37 C with 5% CO2 for the indicated
times. The final content of ethanol was standardized to 0.05%.
Kinetics experiments for cells with overexpression or knock
down of respective genes were carried out after transfection with
100 nM siRNAs and recombinant plasmid for 48 hours. A final
Figure 6. Double-reciprocal plot of 17b-HSD1 catalyzing estrone reduction in HEK-293-17b-HSD1 (A) and T47D (B). 1,000 HEK-293-
17b-HSD1 cells and 40,000 T47D cells were seeded onto 24-well plates. E1 concentrations varied from 0.01 mM to 0.3 mM. Initial velocities were
measured with less than 10% substrate consumption. The final concentration of ethanol was standardized to 0.05% in all reactions.
doi:10.1371/journal.pone.0029835.g006
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medium and the cell supernatants were collected after incubation
at 37 C with 5% CO2 for 24 hours.
When evaluating Km values in T47D and HEK-293-17b-
HSD1 cells, the concentrations of E1 varied from 0.01 mMt o
0.3 mM. Different numbers of cells were used for these two cell
lines and initial velocities were measured with less than 10% of
substrate consumption. E1 was added to the medium and the
reaction was stopped at 0 min, 10 min, 20 min and 30 min.
After the incubation, the steroids were extracted with 3 volumes
of diethyl ether on ethanol dry ice bath. The organic phase was
evaporated, dissolved in 50 ml dichloromethane, applied to Silica
gel 60 thin layer chromatography plates (Merck, Darmstad,
Germany), and separated by migration in a toluene-acetone (4:1,
v/v) solvent system. TLC plates were exposed and quantified using
a storm imaging system (Molecular Dynamics, Sunnyvale, CA).
Cell proliferation analysis
Cell proliferation was determined by the 3-(4, 5-Dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. 50,000 cells
were plated into each well of a 24-well plate, and different
concentrations of E1 and E2 (0.01 mM, 0.05 mM, 0.1 mMa n d
0.3 mM) were added to the medium. MTT assays were carried out
after24 hoursfollowingthemanufacturer’sinstructions.Absorbency
was measured on a plate reader (Spectra Max 340PC, Molecular
Devices, Sunnyvale, CA) at 570 nm, with 630 nm as a reference.
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